ギラン・バレー症候群治療の世界市場2019-2023...市場調査レポートについてご紹介

【英文タイトル】Global Guillain-Barré Syndrome Treatment Market 2019-2023

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
• PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Immunoglobulins – Market size and forecast 2018-2023
• Other therapeutics – Market size and forecast 2018-2023
• Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Americas – Market size and forecast 2018-2023
• EMEA – Market size and forecast 2018-2023
• APAC – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: TRENDS
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• CSL
• Grifols
• Kedrion
• Octapharma
• Shire
PART 14: APPENDIX
• Research methodology
• List of abbreviations
PART 15: EXPLORE TECHNAVIO


Exhibit 01: Global neurological disorder drugs market
Exhibit 02: Segments of global neurological disorder drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition – Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition – Five forces 2018
Exhibit 17: Product – Market share 2018-2023 (%)
Exhibit 18: Comparison by product
Exhibit 19: Immunoglobulins – Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Immunoglobulins – Year-over-year growth 2019-2023 (%)
Exhibit 21: Other therapeutics – Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Other therapeutics – Year-over-year growth 2019-2023 (%)
Exhibit 23: Market opportunity by product
Exhibit 24: Customer landscape
Exhibit 25: Market share by geography 2018-2023 (%)
Exhibit 26: Geographic comparison
Exhibit 27: Americas – Market size and forecast 2018-2023 ($ millions)
Exhibit 28: Americas – Year-over-year growth 2019-2023 (%)
Exhibit 29: Top 3 countries in Americas
Exhibit 30: EMEA – Market size and forecast 2018-2023 ($ millions)
Exhibit 31: EMEA – Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in EMEA
Exhibit 33: APAC – Market size and forecast 2018-2023 ($ millions)
Exhibit 34: APAC – Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in APAC
Exhibit 36: Key leading countries
Exhibit 37: Market opportunity
Exhibit 38: Impact of drivers and challenges
Exhibit 39: Vendor landscape
Exhibit 40: Landscape disruption
Exhibit 41: Vendors covered
Exhibit 42: Vendor classification
Exhibit 43: Market positioning of vendors
Exhibit 44: CSL – Vendor overview
Exhibit 45: CSL – Business segments
Exhibit 46: CSL – Organizational developments
Exhibit 47: CSL – Geographic focus
Exhibit 48: CSL – Segment focus
Exhibit 49: CSL – Key offerings
Exhibit 50: CSL – Key customers
Exhibit 51: Grifols – Vendor overview
Exhibit 52: Grifols – Business segments
Exhibit 53: Grifols – Organizational developments
Exhibit 54: Grifols – Geographic focus
Exhibit 55: Grifols – Segment focus
Exhibit 56: Grifols – Key offerings
Exhibit 57: Grifols – Key customers
Exhibit 58: Kedrion – Vendor overview
Exhibit 59: Kedrion – Business segments
Exhibit 60: Kedrion – Organizational developments
Exhibit 61: Kedrion – Geographic focus
Exhibit 62: Kedrion – Segment focus
Exhibit 63: Kedrion – Key offerings
Exhibit 64: Kedrion – Key customers
Exhibit 65: Octapharma – Vendor overview
Exhibit 66: Octapharma – Organizational developments
Exhibit 67: Octapharma – Key offerings
Exhibit 68: Octapharma – Key customers
Exhibit 69: Shire – Vendor overview
Exhibit 70: Shire – Business segments
Exhibit 71: Shire – Organizational developments
Exhibit 72: Shire – Geographic focus
Exhibit 73: Shire – Key offerings
Exhibit 74: Shire – Key customers



【レポート販売概要】

■ タイトル:ギラン・バレー症候群治療の世界市場2019-2023
■ 英文:Global Guillain-Barré Syndrome Treatment Market 2019-2023
■ 発行日:2018年11月8日
■ 調査会社:Technavio
■ 商品コード:IRTNTR30224
■ 調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。